The positive outcome of the Phase 3 trial is a significant milestone for Iterum Therapeutics, likely to boost investor confidence and potentially increase the stock's value in the short term. The announcement of strategic plans to maximize stakeholder value through selling, licensing, or disposing of the rights to sulopenem could also be viewed positively by the market. However, the actual impact on the stock price will depend on market perception of the company's future prospects and the potential success of the drug.